Relaxin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Relaxin 1
| |
| Identifiers | |
| Symbol | RLN1 |
| Entrez | 6013 |
| HUGO | 10026 |
| OMIM | 179730 |
| Other data | |
| Locus | Chr. 9 qter-q12 |
| Relaxin 2
| |
| Identifiers | |
| Symbol | RLN2 |
| Entrez | 6019 |
| HUGO | 10027 |
| OMIM | 179740 |
| Other data | |
| Locus | Chr. 9 qter-q12 |
| Relaxin 3
| |
| Identifiers | |
| Symbol | RLN3 |
| Entrez | 117579 |
| HUGO | 17135 |
| OMIM | 606855 |
| Other data | |
| Locus | Chr. 19 p13.3 |
|
WikiDoc Resources for Relaxin | |
|
Articles | |
|---|---|
|
Most recent articles on Relaxin | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Relaxin at Clinical Trials.gov Clinical Trials on Relaxin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Relaxin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Relaxin Risk calculators and risk factors for Relaxin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Relaxin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Relaxin is a peptide hormone that was first described in 1926 by Frederick Hisaw.[1][2]
Different forms of relaxin have been described: relaxin 1, 2, and 3.
Production
In the female, it is produced by the corpus luteum of the ovary, the breast and, during pregnancy, also by the placenta, chorion, and decidua.
In the male, relaxin is produced in the testes.
Structure
Structurally, relaxin is a heterodimer of two peptide chains of 24 and 29 amino acids that are linked by disulfide bridges and it appears related to insulin. Relaxin is produced from its prohormone, “pro-relaxin”, by splitting off one additional peptide chain.
Function
In women relaxin levels rise after ovulation as a result of its production by the corpus luteum. In the absence of pregnancy its level declines at menstruation. During the first trimester of pregnancy levels rise and additional relaxin is produced by the decidua.
Relaxin's role or necessity in human pregnancy remains under investigation, as in humans its peak is reached during the first trimester, not toward the end of pregnancy.
In animals relaxin widens the pubic bone and facilitates labor, it also softens the cervix (cervical ripening), and relaxes the uterine musculature. Thus, for a long time, relaxin was looked at as a pregnancy hormone. However, its significance may reach much further. Relaxin affects collagen metabolism, inhibiting collagen synthesis and enhancing its breakdown by increasing matrix metalloproteinases.[3] It also enhances angiogenesis and is a potent renal vasodilator.
Receptors
Relaxin interacts with the relaxin receptor LGR7 (RXFP1) and LGR8 (RXFP2) which belong to the G-protein-coupled receptor superfamily. They contain a heptahelical transmembrane domain and a large glycosylated ectodomain, distantly related to the receptors for the glycoproteohormones, such as the LH-receptor or FSH-receptor.
Relaxin receptors have been found in the heart, smooth muscle, the connective tissue, and central and autonomous nervous system.
Disorders
Specific disorders related to relaxin have not been described, yet it has been suggested that it could be linked to scleroderma and to fibromyalgia.[4]
References
- ↑ http://www.time.com/time/magazine/article/0,9171,796530,00.html
- ↑ Becker G, Hewitson T (2001). "Relaxin and renal fibrosis". Kidney Int 59 (3): 1184-5. PMID 11231378.
- ↑ Mookerjee I, Solly N, Royce S, Tregear G, Samuel C, Tang M (2006). "Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease". Endocrinology 147 (2): 754-61. PMID 16254028.
- ↑ Van Der Westhuizen E, Summers R, Halls M, Bathgate R, Sexton P (2007). "Relaxin receptors--new drug targets for multiple disease states". Curr Drug Targets 8 (1): 91-104. PMID 17266534.
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
